Ice, juice, the exact measure of liquor, a few drops of Angostura... What goes into a good New Year’s Eve cocktail? According to researchers working on vaccines for the most elusive viruses, it will be time soon to toast next-generation vaccines. If 2020 was the year of the COVID-19 pandemic, and in 2021 the year of mRNA vaccinations, 2022 brought polyvalent designs of antigens, evaluated highly neutralizing antibodies, and fine-tuned mRNA technology against SARS-CoV-2, HIV and the flu. Read More
Tucked into the 4,155-page, $1.7 trillion spending bill for fiscal 2023 that U.S. President Joe Biden signed into law Dec. 23 is a small provision that may have outsized impact on future biosimilar and other drug development. Championed by lawmakers on both sides of the political spectrum, the provision modernizes the data that can be used to support drug development, including alternatives to animal studies. Read More
Simcere Pharmaceutical Group Ltd. has received IND approval from China's National Medical Products Administration (NMPA) for two immuno-oncology bispecific antibodies, SIM-0348 and SIM-0237. Read More
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in persons over the age of 50. While poorly understood, AMD pathogenesis begins with structural disorganization of the outer-blood-retina-barrier (oBRB), containing retinal pigment epithelium (RPE) and associated Bruch’s membrane. Read More
Transcode Therapeutics Inc. has received clearance from the FDA to proceed with a first-in-human phase 0 trial of TTX-MC138 in cancer patients with advanced solid tumors. A single dose of radiolabeled TTX-MC138 will be followed by noninvasive PET-MRI to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions. Read More
The primary reason for hospitalization of patients with sickle cell disease (SCD) is an acute systemic painful vaso-occlusive episode (VOE), which serves as an antecedent to acute chest syndrome (ACS). It has been previously demonstrated that P-selectin-dependent neutrophil-platelet aggregation and the complement pathway activation contribute to the vaso-occlusive pathophysiology in SCD. Read More
Researchers from Nanjing University and China Pharmaceutical University have reported the discovery and preclinical evaluation of a novel KRAS(G12C) inhibitor. Read More
Impact Therapeutics (Shanghai) Inc. has synthesized nitrogen-containing fused heteroaromatic bicyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer. Read More
Janssen R&D (Ireland) and Johnson & Johnson (China) Investment Ltd. have disclosed fused heterocyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) infections. Read More
Asieris Pharmaceuticals Co. Ltd. has divulged 7-nitro-8-hydroxyquinoline derivatives reported to be useful for the treatment of urinary tract infections, and bladder and prostate cancer. Read More
Janssen Pharmaceutica NV and Johnson & Johnson (China) Investment Ltd. have identified substituted phenyl-1H-pyrrolo [2, 3-c] pyridine derivatives acting as menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer. Read More
Rewind Therapeutics NV has described 3-pyrrolylsulfonamide compounds acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-like) antagonists reported to be useful for diagnosis and treatment of neurodegeneration, leukodystrophies, optic neuropathy, Charcot-Marie-Tooth disease, demyelinating, psychiatric and genetic disorders, among others. Read More
